dc.contributor.author | Zhang, J | |
dc.contributor.author | Deng, X | |
dc.contributor.author | Kahle, KT | |
dc.date.accessioned | 2018-07-06T14:18:37Z | |
dc.date.issued | 2016-10-18 | |
dc.description.abstract | The with-no-lysine (K) WNK kinases are master regulators of the Na+-(K+)-Cl- cotransporters, including the renal-specific NCC and NKCC2 cotransporters. The discovery of WNK463, an orally bioavailable pan-WNK kinase inhibitor that exploits unique structural properties of the WNK catalytic domain to achieve high affinity and kinase selectivity, illustrates a strategy of leveraging distinct kinase features to develop specific inhibitors and validates the genetic predictions of the in vivo pharmacology of WNK inhibition. | en_GB |
dc.identifier.citation | Vol. 9 (450), pp. pe3. | en_GB |
dc.identifier.doi | 10.1126/scisignal.aaj2227 | |
dc.identifier.uri | http://hdl.handle.net/10871/33391 | |
dc.language.iso | en | en_GB |
dc.publisher | American Association for the Advancement of Science | en_GB |
dc.relation.url | https://www.ncbi.nlm.nih.gov/pubmed/27811182 | en_GB |
dc.rights | Copyright © 2016, American Association for the Advancement of Science | en_GB |
dc.subject | Animals | en_GB |
dc.subject | Humans | en_GB |
dc.subject | Imidazoles | en_GB |
dc.subject | Protein-Serine-Threonine Kinases | en_GB |
dc.subject | Pyrrolidines | en_GB |
dc.subject | Solute Carrier Family 12, Member 1 | en_GB |
dc.title | Leveraging unique structural characteristics of WNK kinases to achieve therapeutic inhibition | en_GB |
dc.type | Article | en_GB |
dc.date.available | 2018-07-06T14:18:37Z | |
dc.identifier.issn | 1945-0877 | |
exeter.place-of-publication | United States | en_GB |
dc.description | This is the author accepted manuscript. The final version is available from American Association for the Advancement of Science via the DOI in this record. | en_GB |
dc.identifier.journal | Science Signaling | en_GB |